NCT06593782View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

June 11, 2025

Study Completion Date

September 1, 2025

Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
DRUG

HSK21542

"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"

DRUG

HSK21542

"1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"

DRUG

Dolasetron

"1. Placebo to match HSK21542 injection was administered day 1;~2. Dorasetron injection was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;"

All Listed Sponsors
lead

First Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06593782 - Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting | Biotech Hunter | Biotech Hunter